Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Intraspinal Steroids: History, Efficacy, Accidentality, and Controversy with Review of United States Food and Drug Administration Reports
JNNP 70:433-443, Nelson,D.A. & Landau,W.M., 2001
Idiopathic Normal-Pressure Hydrocephalus
NEJM 393:2243-2253, 2264, Johnson,M.D.,& Williams, M.A., 2025
Patent Foramen Ovale Management for Secondary Stroke Prevention:State-of-the-Art Appraisal of Current Evidence
Stroke 55:236-247, Sposato,L.A.,et al, 2024
Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Cognitive Motor Dissociation in Disorders of Consciousness
NEJM 391:598-608, Bodien,Y.G.,et al, 2024
Anticoagulation vs Antiplatelets Across Subgroups of Embolic Stroke of Undetermined Source
Neurol 103:e209949, Grannam,M.,et al, 2024
Primary Diffuse Leptomeningeal Melanocytosis, A Diagnoatic Conundrum
Neurol 101:e576-3580, Selvarajan,J.M.P.,et al, 2023
Endovascular Treatment and Thrombolysis for Acute Ischemic Stroke in Patients with Premorbid Disability or Dementia
Stroke 53:e204-e217, Ganesh, A.,et al, 2022
Five-Year Outcomes of PFO Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 384:970-971, , 2021
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Determination of Brain Death
NEJM 385:2554-2561, Greer, D.M., 2021
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020
Tailoring the Approach to Embolic Stroke of Undetermined Source
JAMA Neurol 76:855-861, Kamel, H.,et al, 2019
Debate Sparks Over LATE, a Recently Recognized Dementia
JAMA 322:914-916, Abbasi, J., 2019
Neurological Manifestations Among US Government Personnel Reporting Directional Audible and Sensory Phenomena in Havana, Cuba
JAMA 319:1125-1133, 1098, 1079, Swanson, R.L.,et al, 2018
PFO Closure for Cryptogenic Stroke
NEJM 378:1639-1642, Mi, M.Y.,et al, 2018
Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation Therapy Alone for Management of Cryptogenic Stroke?
BMJ 362:k2515, Kuijpers, T.,et al, 2018
Ethical, Palliative, and Policy Considerations in Disorders of Consciousness
Neurol 91:471-475, Fins, J.J. & Bernat, J.L., 2018
Cardiac Magnetic Resonance Imaging: A New Tool to Identify Cardioaortic Sources in Ischaemic Stroke
JNNP 88:31-37, Yaghi, S.,et al, 2017
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 377:1033-1042,1006,1093, Sondergaard, L.,et al, 2017
Chess Study Revives Debate Over Cognition-Enhancing Drugs
JAMA doi:10.1001/JAMA:2017.8114, Lyon, J., 2017
Hydrocephalus in Children
Lancet 387:788-799, Kahle, K.T.,et al, 2016
Closure Versus Medical Therapy for Preventing Recurrent Stroke in Patients with Patent Foramen Ovale and a History of Cryptogenic Stroke or Transient Ischemic Attack
Stroke 47:e188-e189, Li, J.,et al, 2016
Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Juvenile Metachromatic Leukodystrophy Compared with Nontransplanted Control Patients
JAMA Neurol 73:1133-1140, Groeschel, S.,et al, 2016
Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension
NEJM 375:1119-1130,1183, Hutchinson, P.J.,et al, 2016
Review of the Utility of Prophylactic Anticonvulsant Use in Critically Ill Patients with Intracerebral Hemorrhage
Stroke 47:2666-2672, Gilmore, E.J.,et al, 2016
Non-Alzheimers Dementia 3 Vascular Dementia
Lancet 386:1698-1706, OBrien, J.T. & Thomas, A., 2015
Newborn Screening for Fragile X Syndrome
JAMA Neurol 71:355-359, Tassone, F., 2014
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
The Eye of the Beholder: Inter-rater Agreement among Experts on Psychogenic Jerky Movement Disorders
JNNP 84:742-747, Van de Salm, S.,et al, 2013
An Index to Identify Stroke-Related vs Incidental Patent Foramen Ovale in Cryptogenic Stroke
Neurol 81:619-625,619, Kent, D.M.,et al, 2013
Patent Foramen Ovale and Cryptogenic Stroke
Stroke 44:2676-2678, Furlan, A.J. and Jauss, M., 2013
Left Atrial Catheter Ablation and Ischemic Stroke
Stroke 43:265-270, Haeusler, K.G.,et al, 2012
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
NEJM 366:991-999,1048, Furlan,A.J.,et al, 2012
Seizure risk with AVM Treatment or Conservative Management
Neurol 79:500-507, Josephson, C.B.,et al, 2012
Willful Modulation of Brain Activity in Disorders of Consciousness
NEJM 362:579-589,648, Monti,M.M.,et al, 2010
The Case Against Confirmatory Tests for Determining Brain Death in Adults
Neurol 75:77-83, Wijdicks,E.F.M., 2010
Disclosure of APOE Genotype for Risk of Alzheimers Disease
NEJM 361:245-254,298, Green,R.C.,et al, 2009
Risk of Dementia and AD with Prior Exposure to NSAIDs in an Elderly Community-Based Cohort
Neurol 72:1899-1905,1884, Breitner,J.C.S.,et al, 2009
Responding to Requests from Adult Patients for Neuroenhancements
Neurol 73:1406-1412, Larriviere,D.,et al, 2009
Safety and Efficacy of Galantamine in Subjects with Mild Cognitive Impairment
Neurol 70:2024-2035, Winblad,B.,et al, 2008
Media Coverage of the Persistent Vegetative State and End-of-Life Decision-Making
Neurol 71:1027-1032,964, Racine,E.,et al, 2008
Dementia Screening in Primary Care: Is It Time?
JAMA 298:2409-2411, Brayne,C.,et al, 2007
Multiple-Level Studies Are Needed to Assess the True Value of Diagnostic Tests for Dementia
Arch Neurol 63:142-143,146, Van Gool,W.A., 2006